GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guided Therapeutics Inc (OTCPK:GTHP) » Definitions » Gross Margin %

Guided Therapeutics (Guided Therapeutics) Gross Margin % : 50.00% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Guided Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Guided Therapeutics's Gross Profit for the three months ended in Dec. 2023 was $0.02 Mil. Guided Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.03 Mil. Therefore, Guided Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was 50.00%.


The historical rank and industry rank for Guided Therapeutics's Gross Margin % or its related term are showing as below:

GTHP' s Gross Margin % Range Over the Past 10 Years
Min: -523.08   Med: 1.57   Max: 140.2
Current: 36.74


During the past 13 years, the highest Gross Margin % of Guided Therapeutics was 140.20%. The lowest was -523.08%. And the median was 1.57%.

GTHP's Gross Margin % is ranked worse than
72.24% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.135 vs GTHP: 36.74

Guided Therapeutics had a gross margin of 50.00% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Guided Therapeutics was 0.00% per year.


Guided Therapeutics Gross Margin % Historical Data

The historical data trend for Guided Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guided Therapeutics Gross Margin % Chart

Guided Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -94.44 140.20 24.69 -523.08 36.73

Guided Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 59.09 25.00 - 50.00

Competitive Comparison of Guided Therapeutics's Gross Margin %

For the Medical Devices subindustry, Guided Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guided Therapeutics's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Guided Therapeutics's Gross Margin % falls into.



Guided Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Guided Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0 / 0.098
=(Revenue - Cost of Goods Sold) / Revenue
=(0.098 - 0.062) / 0.098
=36.73 %

Guided Therapeutics's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 0.032
=(Revenue - Cost of Goods Sold) / Revenue
=(0.032 - 0.016) / 0.032
=50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Guided Therapeutics  (OTCPK:GTHP) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Guided Therapeutics had a gross margin of 50.00% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Guided Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Guided Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Guided Therapeutics (Guided Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5835 Peachtree Corners East, Suite B, Norcross, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
Executives
John E Imhoff director, 10 percent owner P.O. BOX 31083, SEA ISLAND GA 31561
Alan Grujic director 349 FORBES AVE, SAN RAFAEL CA 94901
Michael C James director 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Richard P. Blumberg director 2357 HOBART AVENUE S.W., SEATTLE WA 98116
Lynne H Imhoff 10 percent owner 2716 SOUTH ROCKFORD ROAD, TULSA OK 74114
Gene S Cartwright officer: Chief Executive Officer 4088 COMMERCIAL AVE, NORTHBROOK IL 60062
Parsons & Whittemore Enterprises Corp. 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 10-year Grat 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F Landegger 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK, NEW YORK NY 10573
Whittemore Collection Ltd 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 5-year Grat 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Linda Rosenstock director 5995 PLAZA DRIVE, MAIL STOP CY20-103, CYPRESS CA 90630
Jonathan M Niloff director C/O MATRITECH, INC., 330 NEVADA STREET, NEWTON MA 02460
Ronald W Allen director P O BOX 1734, ATLANTA GA 30301
Shabbir Bakir Bambot officer: VP of R & D 4955 AVALON RIDGE PARKWAY, SUITE 300, NORCROSS GA 30071

Guided Therapeutics (Guided Therapeutics) Headlines